Reuters reports that the U.S. administration, under President Donald Trump, is expected to announce the results of a probe into pharmaceutical imports and introduce new sector-specific tariffs within the next few weeks, although this timeline is later than initially anticipated. The announcement is expected to impact major publicly traded pharmaceutical companies such as AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, and Sanofi.

DelveInsight's 2025 report provides a comprehensive analysis of the metastatic renal cell carcinoma (mRCC) pipeline, covering 40+ companies and 50+ pipeline drugs across various stages of development. The report details clinical and nonclinical drug profiles, including therapeutic assessments by product type, stage, route of administration, and molecular mechanism. It highlights key companies such as AstraZeneca, Genentech, Sumitomo Dainippon Pharma, and others, and outlines specific therapies like Olaparib, Atezolizumab, and TP-1454 in different clinical phases. The report also discusses ongoing clinical trials, including a phase II trial by the Ontario Clinical Oncology Group evaluating SBRT combined with I/N therapy for intermediate/poor risk mRCC patients. It includes information on inactive pipeline products and provides insights into collaborations, licensing, and financing strategies shaping the mRCC market.

DelveInsight's 2025 report provides a comprehensive analysis of the metastatic renal cell carcinoma (mRCC) pipeline, covering 40+ companies and 50+ pipeline drugs across various stages of development. The report details clinical and nonclinical drug profiles, therapeutic assessments by product type, stage, route of administration, and molecular mechanism. It highlights key companies such as AstraZeneca, Genentech, Sumitomo Dainippon Pharma, and others, and outlines specific therapies like Olaparib, Atezolizumab, and TP-1454 in different phases of clinical trials. The report also includes information on inactive pipeline products, collaborations, and market dynamics, with a focus on emerging treatments and unmet medical needs in mRCC.

DelveInsight's 2025 Biliary Tract Cancer Pipeline Report provides a comprehensive analysis of 80+ companies and 80+ pipeline therapies in the biliary tract cancer space. The report details clinical and nonclinical stage drug profiles, including assessments by product type, stage, route of administration, and molecule type. Key studies announced in August 2025 include AstraZeneca's evaluation of durvalumab with gemcitabine-based chemo, Eli Lilly's trial of ramucirumab or merestinib with cisplatin and gemcitabine, Boehringer Ingelheim's investigation of BI 907828 (an MDM2 inhibitor), Seagen's study on tucatinib for HER2-altered solid tumors, and Incyte's Phase 1/2 trial of INCB001158. The report highlights several promising therapies such as PEMAZYRE, ROZLYTREK, VITRAKVI, TIBSOVO, LYTGOBI, KEYTRUDA, and IMFINZI. It also features detailed profiles of drugs like MRG 002 (Miracogen), Disitamab Vedotin (Yantai Rongchang Pharmaceutical), Envafolimab (Alphamab Oncology), and DKN-01 (Leap Therapeutics), including their mechanisms, development stages, and regulatory designations. The report covers global companies and therapies, with a focus on pipeline activity, unmet needs, and market dynamics.

The Texas Attorney General has accused Eli Lilly of offering assistance programs that constitute bribes, raising concerns about the ethics and compliance of pharmaceutical incentives. This claim is set against a broader context of growing diabetes drug market expansion in Saudi Arabia, driven by rising diabetes prevalence, government initiatives under Vision 2030, and increased adoption of advanced therapeutics like GLP-1 receptor agonists and SGLT2 inhibitors. Key players such as Novo Nordisk, Sanofi, AstraZeneca, and Eli Lilly are involved in market growth through drug development, distribution, and localization efforts, including a 2024 agreement to localize insulin production. Despite strong government investment in healthcare and public awareness, challenges remain in affordability, rural access, and awareness, particularly for newer, more expensive medications.